Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics and biosimilars, revenue has trended […]
It’s not often that $10 trillion markets appear. But that’s exactly what is happening right now with the robotaxi market. “We think US$8 [trillion] to […]